ASO treatment for SCN2A-encephalopathy, allele-specific vs non-specific
September 11, 2023 12:30-1:30 pm US EST - We will discuss the idea of ASO treatment for gain-of-function SCN2A-encephalopathy, including...
Who We Are
ASO treatment for SCN2A-encephalopathy, allele-specific vs non-specific
Selecting the right candidate: Which disease-causing variants are eligible for N=1 ASOs?
August Newsletter
Q&A: FDA's Peter Marks ready to encourage more accelerated approvals for rare diseases
Too many treatable diseases go unnoticed. This could change that.
‘This is not a science problem anymore': Paths emerge for scaling up rare disease medicine
The quest for the era of personalised medicine
From Mutation to Dose-able CRISPR Medicine In 3 Months: Obstacles & Actionable Paths Forward